Literature DB >> 22482710

Broadly neutralizing antibodies against influenza virus and prospects for universal therapies.

Damian C Ekiert1, Ian A Wilson.   

Abstract

Vaccines are the gold standard for the control and prevention of infectious diseases, but a number of important human diseases remain challenging targets for vaccine development. An influenza vaccine that confers broad spectrum, long-term protection remains elusive. Several broadly neutralizing antibodies have been identified that protect against multiple subtypes of influenza A viruses, and crystal structures of several neutralizing antibodies in complex with the major influenza surface antigen, hemagglutinin, have revealed at least 3 highly conserved epitopes. Our understanding of the molecular details of these antibody-antigen interactions has suggested new strategies for the rational design of improved influenza vaccines, and has inspired the development of new antivirals for the treatment of influenza infections.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22482710      PMCID: PMC3368890          DOI: 10.1016/j.coviro.2012.02.005

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  30 in total

1.  Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Bryan S Briney; Scott A Smith; Christopher F Basler; James E Crowe
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

2.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

3.  The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region.

Authors:  H Sagawa; A Ohshima; I Kato; Y Okuno; Y Isegawa
Journal:  J Gen Virol       Date:  1996-07       Impact factor: 3.891

4.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.

Authors:  J E Crowe; P S Gilmour; B R Murphy; R M Chanock; L Duan; R J Pomerantz; G R Pilkington
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

Review 7.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

8.  A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein.

Authors:  Yong-Qiang Deng; Jian-Xin Dai; Guang-Hui Ji; Tao Jiang; Hua-Jing Wang; Hai-ou Yang; Weng-Long Tan; Ran Liu; Man Yu; Bao-Xue Ge; Qing-Yu Zhu; E-De Qin; Ya-Jun Guo; Cheng-Feng Qin
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

9.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

10.  Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.

Authors:  P B Rosenthal; X Zhang; F Formanowski; W Fitz; C H Wong; H Meier-Ewert; J J Skehel; D C Wiley
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

View more
  80 in total

1.  Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Authors:  Chi-Jene Chen; Megan E Ermler; Gene S Tan; Florian Krammer; Peter Palese; Rong Hai
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

2.  Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin.

Authors:  Peter H Goff; Florian Krammer; Rong Hai; Christopher W Seibert; Irina Margine; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

3.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Authors:  Guha Asthagiri Arunkumar; Andriani Ioannou; Teddy John Wohlbold; Philip Meade; Sadaf Aslam; Fatima Amanat; Juan Ayllon; Adolfo García-Sastre; Florian Krammer
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection.

Authors:  Xiang Wang; Ping Zhou; Mangteng Wu; Kaiyan Yang; Jingao Guo; Xuchen Wang; Jun Li; Zihao Fang; Guiqin Wang; Man Xing; Dongming Zhou
Journal:  NPJ Vaccines       Date:  2020-07-09       Impact factor: 7.344

5.  Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Authors:  Florian Krammer; Natalie Pica; Rong Hai; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

6.  Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein.

Authors:  Lenore L Carias; Sebastien Dechavanne; Vanessa C Nicolete; Sokunthea Sreng; Seila Suon; Chanaki Amaratunga; Rick M Fairhurst; Celia Dechavanne; Samantha Barnes; Benoit Witkowski; Jean Popovici; Camille Roesch; Edwin Chen; Marcelo U Ferreira; Niraj H Tolia; John H Adams; Christopher L King
Journal:  J Immunol       Date:  2019-04-03       Impact factor: 5.422

7.  High-throughput identification of loss-of-function mutations for anti-interferon activity in the influenza A virus NS segment.

Authors:  Nicholas C Wu; Arthur P Young; Laith Q Al-Mawsawi; C Anders Olson; Jun Feng; Hangfei Qi; Harding H Luan; Xinmin Li; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

Review 8.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

9.  Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.

Authors:  Edwin Chen; Nichole D Salinas; Yining Huang; Francis Ntumngia; Manolo D Plasencia; Michael L Gross; John H Adams; Niraj Harish Tolia
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-18       Impact factor: 11.205

10.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.